相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Biochemistry & Molecular Biology
Mengxin Zhang et al.
Summary: Vaccines have shown to be highly effective in reducing hospitalization and deaths caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, a deadly second wave of COVID-19, caused by SARS-CoV-2 variants, especially the Delta variant, has led to an increased number of breakthrough infections in vaccinated individuals. The Delta variant not only results in a surge of breakthrough infections with high viral load and transmissibility, but also poses a challenge to the development of effective vaccines.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Immunology
Barbaros Eroglu et al.
Summary: The COVID-19 pandemic has had catastrophic impacts globally, and the development of vaccines has been considered the best tool to minimize its effects. Although vaccines have been available and in use for some time, the pandemic is expected to persist due to various factors such as reduced compliance with public health measures, limited vaccine manufacturing and distribution capacity, and the emergence of new variants.
Article
Infectious Diseases
Payam Tabarsi et al.
Summary: The SpikoGen (R) vaccine has a good safety profile and induces promising immune responses against SARS-CoV-2. Previously infected individuals show a significant immune response after a single dose of the vaccine.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Medicine, General & Internal
Minoo Mohraz et al.
Summary: This study assessed the safety and immunogenicity of an inactivated whole virus particle vaccine. The results showed that the vaccine had good safety profile in all stages and could effectively induce neutralizing antibodies and antibody responses.
Article
Biotechnology & Applied Microbiology
Dmitry Kudlay et al.
Summary: This review evaluates the current state of COVID-19 vaccine development, discussing issues such as vaccine effectiveness, long-term efficacy, and stability. The impact of SARS-CoV-2 variants on vaccine efficacy is also addressed, although most vaccines remain effective. Additionally, the use of different platforms within a vaccination course is considered as a promising strategy to improve vaccine effectiveness.
BIOENGINEERING-BASEL
(2022)
Article
Medicine, General & Internal
Minoo Mohraz et al.
Summary: The study aimed to assess the safety and immunogenicity of an inactivated whole virus particle vaccine. The results indicated that the vaccine demonstrated good safety and immunogenicity in the trials.
Article
Immunology
Soheil Ghasemi et al.
Summary: This study evaluated the potency and safety of an inactivated SARS-CoV-2 vaccine candidate (FAKHRAVAC) in a preclinical study, showing that this vaccine candidate induced neutralizing antibodies in various animal models and achieved a 100% seroconversion rate in tested animals after 28 days of immunization. These results support further evaluation of FAKHRAVAC in clinical trials.
Review
Biochemistry & Molecular Biology
Ramesh Kandimalla et al.
Summary: The emergence of SARS-CoV-2 in late 2019 led to the COVID-19 pandemic, prompting rapid development of multiple vaccine candidates which have been commercialized in 2021. While these vaccines showed promising results, key insights into their epidemiology, protective mechanisms, and reinfection tendencies are lacking. This report provides insights into vaccination prospects, diverse strategies, approved vaccines, success rates, and potential challenges for the future.
Review
Biochemistry & Molecular Biology
Jean-Louis Excler et al.
Summary: Studies on COVID-19 vaccination strategies in comparison to previous infectious diseases offer critical lessons for future public health emergencies. The unprecedented scale and rapid spread of emerging infectious diseases present new challenges for vaccine development and distribution. Prioritizing access to vaccines in low- and middle-income countries, along with close monitoring of vaccine safety and virus variants, will be crucial for the success of pandemic control efforts.
Article
Social Issues
Mehdi Majidpour et al.
Summary: This paper examines the market and technological capabilities required for technological catch-up in the biopharmaceutical sector through a multi-case study method. It highlights the importance of strong R&D efforts in the early stages as a prerequisite for technological growth. Additionally, it suggests that assimilated migratory knowledge can stimulate further technological capability-building efforts by local firms.
TECHNOLOGY IN SOCIETY
(2021)
Article
Immunology
Lei Li et al.
Summary: The development of Covax-19, a recombinant spike protein vaccine, induced high levels of immune response and protected ferrets from SARS-CoV-2 virus challenge. Results suggest that the vaccine not only protects the lungs from infection but also has the potential to reduce virus transmission.
Review
Immunology
Shrina P. Patel et al.
Summary: The coronavirus pandemic has led to a global health emergency, with vaccines being developed in a race against time. The challenge lies in the rigorous testing required for vaccines, while the public faces the challenge of sifting through an abundance of information and myths.
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH
(2021)
Article
Immunology
Abdel-Hameed Al-Mistarehi et al.
Summary: The study in Jordan revealed variations in the acceptance of the COVID-19 vaccine among different demographic groups, with higher rates of acceptance observed among younger adults, males, unmarried individuals, those with higher education levels, healthcare workers, and individuals who had received the flu vaccine. Safety and side effects were highlighted as common concerns among individuals who were hesitant or unwilling to take the COVID-19 vaccine.
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH
(2021)
Article
Business
James M. Crick et al.
INDUSTRIAL MARKETING MANAGEMENT
(2020)
Review
Immunology
Seunghoon Han
CLINICAL AND EXPERIMENTAL VACCINE RESEARCH
(2015)
